Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aravive, Inc.VSAR · Entity 114535 | Chief Medical Officer | December 20, 2017 | December 22, 2017 |
| uniQure N.V.QURE · Entity 4162 | Director | June 10, 2026 | June 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aravive, Inc.
Report date December 20, 2017 · Filed December 22, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 227,300 |
Reported balance
After 2017-12-20 transaction · row 1
1 source rowRow 1 · 2017-12-20 · Grant · Acquired 91,300 · Balance 227,300 F1: Represents the grant of Restricted Stock Units that vest as follows: 25% of the shares vest on each of December 20, 2018, December 20, 2019, December 20, 2020 and December 20, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the grant of Restricted Stock Units that vest as follows: 25% of the shares vest on each of December 20, 2018, December 20, 2019, December 20, 2020 and December 20, 2021.
uniQure N.V.
Report date June 10, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 32,259 |
Ending reported balance
After 2026-06-11 transaction · row 6
6 source rows · reconciled sequenceRow 1 · 2026-06-10 · Exercise / conversion · Acquired 2,645 · Balance 34,987 F1: The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on July 8, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. Row 2 · 2026-06-10 · Sale · Disposed 2,645 · Balance 32,342 F1: The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on July 8, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.01 to $26.53. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in the footnote. Row 3 · 2026-06-10 · Sale · Disposed 3,127 · Balance 29,215 F1: The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on July 8, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.01 to $26.18. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in the footnote. Row 4 · 2026-06-10 · Sale · Disposed 1,780 · Balance 27,435 F1: The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on July 8, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F4: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.01 to $26.14 . The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in the footnote. Row 5 · 2026-06-10 · Grant · Acquired 7,550 · Balance 34,985 F5: Represents restricted share units granted to the Reporting Person under the Issuer's 2014 Share Incentive Plan, as amended and restated. Each restricted share unit represents the contingent right to receive one Ordinary Share. The restricted share units vest 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date. Row 6 · 2026-06-11 · Sale · Disposed 2,726 · Balance 32,259 F6: The shares were sold upon the vesting of restricted share units solely to cover estimated withholding taxes, pursuant to automatic sale instructions included in the relevant Restricted Share Unit Agreement. The sale was not a discretionary trade by the Reporting Person. F7: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.92 to $27.25. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in the footnote. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.04 · Expires 2032-02-24 | Direct | 0 |
Reported balance
After 2026-06-10 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-06-10 · Exercise / conversion · Disposed 2,645 · Balance 0 F1: The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on July 8, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F8: The Stock Option vested in full on February 24, 2023. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.82 · Expires 2036-06-10 | Direct | 13,980 |
Reported balance
After 2026-06-10 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-06-10 · Grant · Acquired 13,980 · Balance 13,980 F9: The Stock Option vests 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on July 8, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.
F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.01 to $26.53. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in the footnote.
F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.01 to $26.18. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in the footnote.
F4: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.01 to $26.14 . The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in the footnote.
F5: Represents restricted share units granted to the Reporting Person under the Issuer's 2014 Share Incentive Plan, as amended and restated. Each restricted share unit represents the contingent right to receive one Ordinary Share. The restricted share units vest 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date.
F6: The shares were sold upon the vesting of restricted share units solely to cover estimated withholding taxes, pursuant to automatic sale instructions included in the relevant Restricted Share Unit Agreement. The sale was not a discretionary trade by the Reporting Person.
F7: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.92 to $27.25. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in the footnote.
F8: The Stock Option vested in full on February 24, 2023.
F9: The Stock Option vests 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 19, 2019 Filed Sep 20, 2019 18:00 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 4,769 | $47.16 | $224,906.04 |
DisclosureSEC source: 0000904454-19-000646 · edgar.xml · nonDerivative · entry 1 Gut Robert · CIK 0001716268 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,378 F1 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $46.91 to $ 47.50. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 25, 2019 Filed Jan 29, 2019 23:58 UTC | uniQure N.V. QURE · Entity 4162 | GrantStock Option (Right to Buy) · Derivative | 16,877 | $0.00 Strike: $31.71 | $0.00 |
DisclosureSEC source: 0000904454-19-000096 · edgar.xml · derivative · entry 2 Gut Robert · CIK 0001716268 · Director · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,877 Underlying: Ordinary Shares · 16,877 shares Expires 2029-01-25 F2 · derivative.exercise_date: The Stock Option vests 25% on the first anniversary of the date of grant, and 6.25% quarterly thereafter until fully vested, subject to the Reporting Person's continued relationship with the Issuer through such dates. Read SEC document |
| January 25, 2019 Filed Jan 29, 2019 23:58 UTC | uniQure N.V. QURE · Entity 4162 | GrantOrdinary Shares | 5,147 | $0.00 | $0.00 |
DisclosureSEC source: 0000904454-19-000096 · edgar.xml · nonDerivative · entry 1 Gut Robert · CIK 0001716268 · Director · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,147 F1 · shares: Represents restricted share units granted to the Reporting Person under the Issuer's 2014 Share Incentive Plan, as amended and restated. Each restricted share unit represents the contingent right to receive one Ordinary Share. The restricted share units vest in equal annual installments of 1/3 each, beginning on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such dates. Read SEC document |
| September 18, 2018 Filed Sep 25, 2018 17:56 UTC | uniQure N.V. QURE · Entity 4162 | GrantStock Option (Right to Buy) · Derivative | 70,000 | $0.00 Strike: $39.97 | $0.00 |
DisclosureSEC source: 0000904454-18-000581 · edgar.xml · derivative · entry 2 Gut Robert · CIK 0001716268 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Ordinary Shares · 70,000 shares Expires 2028-09-18 F2 · derivative.exercise_date: The Stock Option vests over four years, with 25% vesting after twelve months from the date of grant and then 6.25% every three months thereafter, subject to the Reporting Person's continued relationship with the Issuer through each such date. Read SEC document |
| September 18, 2018 Filed Sep 25, 2018 17:56 UTC | uniQure N.V. QURE · Entity 4162 | GrantOrdinary Shares | 35,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000904454-18-000581 · edgar.xml · nonDerivative · entry 1 Gut Robert · CIK 0001716268 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 F1 · shares: Represents restricted share units granted to the Reporting Person under the Issuer's 2014 Share Incentive Plan, as amended and restated. Each restricted share unit represents the contingent right to receive one Ordinary Share. The restricted share units vest in thirds on the first, second and third anniversaries of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through each such date. Read SEC document |
| June 14, 2018 Filed Jun 18, 2018 14:38 UTC | uniQure N.V. QURE · Entity 4162 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $35.40 | $0.00 |
DisclosureSEC source: 0000904454-18-000435 · edgar.xml · derivative · entry 1 Gut Robert · CIK 0001716268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Ordinary Shares · 10,000 shares Expires 2028-06-14 F1 · derivative.exercise_date: The Stock Option vests over three years, with one-third vesting after twelve months from the date of grant and then one-twelfth every three months thereafter, subject to the Reporting Person's continued relationship with the Issuer through each such date. Read SEC document |
| December 20, 2017 Filed Dec 22, 2017 17:01 UTC | Aravive, Inc. VSAR · Entity 114535 | GrantCommon Stock | 91,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-067090 · doc4.xml · nonDerivative · entry 1 Gut Robert · CIK 0001716268 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 227,300 F1 · shares: Represents the grant of Restricted Stock Units that vest as follows: 25% of the shares vest on each of December 20, 2018, December 20, 2019, December 20, 2020 and December 20, 2021. Read SEC document |
| October 06, 2017 Filed Oct 10, 2017 20:13 UTC | Aravive, Inc. VSAR · Entity 114535 | GrantCommon Stock | 88,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-056565 · doc4.xml · nonDerivative · entry 1 Gut Robert · CIK 0001716268 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,000 F1 · shares: Represents the grant of Restricted Stock Units that vest as follows: 50% of the shares vest on each of October 6, 2018 and October 6, 2019. Read SEC document |
| September 05, 2017 Filed Sep 6, 2017 18:13 UTC | Aravive, Inc. VSAR · Entity 114535 | GrantStock Option (Right to Buy) · Derivative | 107,000 | $0.00 Strike: $19.80 | $0.00 |
DisclosureSEC source: 0001209191-17-051741 · doc4.xml · derivative · entry 2 Gut Robert · CIK 0001716268 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,000 Underlying: Common Stock · 107,000 shares Expires 2027-09-04 F2 · derivative.exercise_date: Twenty-five percent of the shares subject to the option become exercisable on September 5, 2018 and 1/48th of the shares subject to the option become exercisable monthly thereafter. Read SEC document |
| September 05, 2017 Filed Sep 6, 2017 18:13 UTC | Aravive, Inc. VSAR · Entity 114535 | GrantCommon Stock | 48,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-051741 · doc4.xml · nonDerivative · entry 1 Gut Robert · CIK 0001716268 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,000 F1 · shares: Represents the grant of restricted stock units. Twenty-five percent of the shares subject to the restricted stock units vest on each of September 5, 2018, September 5, 2019, September 5, 2020 and September 5, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.